Dose comparison trial of sustained-release fampridine in multiple sclerosis
- 7 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 71 (15) , 1134-1141
- https://doi.org/10.1212/01.wnl.0000326213.89576.0e
Abstract
Objective: To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS).Keywords
This publication has 30 references indexed in Scilit:
- Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyMultiple Sclerosis Journal, 2007
- Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatmentPharmacology & Therapeutics, 2006
- Recent developments in the assessment of quality of life in Multiple Sclerosis (MS)Multiple Sclerosis Journal, 1999
- Molecular Diversity of K+ ChannelsAnnals of the New York Academy of Sciences, 1999
- 4-Aminopyridine in Patients with Multiple SclerosisClinical Neuropharmacology, 1993
- The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over studyAnnals of Neurology, 1992
- Orally administered 4‐aminopyridine improves clinical signs in multiple sclerosisAnnals of Neurology, 1990
- 4‐Aminopyridine improves clinical signs in multiple sclerosisAnnals of Neurology, 1987
- Poisoning with 4-Aminopyridine: Report of Three CasesClinical Toxicology, 1980
- Effects of 4-aminopyridine in myasthenia gravis.Journal of Neurology, Neurosurgery & Psychiatry, 1979